Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
Roche Holding AG Ordinary Shares new ROP
News
Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
Roche launches newborn screening test for three severe genetic conditions
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
Roche Halts Development of Obesity Drug Candidate
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial — Update
European Pharma Leaders Push for National Reforms to Boost Investment
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
Roche's Susvimo Gets European Union Approval
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center
Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
Hutchmed Enters Licensing Agreement With GSK for Cancer Drug
Roche, Simcere Pharma Strike Drug Licensing Deal
FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly
United States